Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Charalambos Andreadis

Description

Summary

This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.

Official Title

A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma

Keywords

Follicular Lymphoma Refractory or relapsed Follicular Lymphoma Refractory Relapsed CTL019 Tisagenlecleucel Chimeric antigen receptor Lymphoma Lymphoma, Follicular

Eligibility

You can join if…

Open to people ages 18 years and up

  • Refractory or relapsed Follicular Lymphoma (Grade 1, 2, 3A)
  • Radiographically measurable disease at screening

You CAN'T join if...

  • Evidence of histologic transformation
  • Follicular Lymphoma Grade 3B
  • Prior anti-CD19 therapy
  • Prior gene therapy
  • Prior adoptive T cell therapy
  • Prior allogeneic hematopoietic stem cell transplant
  • Active CNS involvement by malignancy

Locations

  • UCSF Medical Center accepting new patients
    San Francisco California 94143 United States
  • City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(1) accepting new patients
    Duarte California 91010 3000 United States

Lead Scientist

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Novartis Pharmaceuticals
ID
NCT03568461
Phase
Phase 2
Study Type
Interventional
Last Updated